During a structured medication review for a 69-year-old man taking 12 regular medications for multiple chronic conditions, you are applying the 7-Steps approach recommended by the General Medical Council. After identifying his current medications (Step 1) and determining which ones are essential, beneficial, or potentially harmful (Step 2), you identify that he is taking two proton pump inhibitors prescribed by different specialists. What is the next most appropriate step in the medication review process?
Q82
A 71-year-old woman with heart failure (NYHA class III), type 2 diabetes, and chronic kidney disease stage 3b attends for her six-monthly review. Her medications include bisoprolol 10mg once daily, ramipril 10mg once daily, spironolactone 25mg once daily, furosemide 80mg twice daily, metformin 500mg twice daily, empagliflozin 10mg once daily, and atorvastatin 40mg at night. Blood tests show: Na+ 136 mmol/L, K+ 5.8 mmol/L, urea 14.2 mmol/L, creatinine 168 µmol/L (eGFR 28 ml/min/1.73m²), HbA1c 58 mmol/mol. What is the single most appropriate immediate medication change?
Q83
A 74-year-old man with type 2 diabetes, hypertension, asthma, and osteoarthritis attends for a medication review. He takes 8 regular medications including metformin, gliclazide, ramipril, amlodipine, beclometasone/formoterol inhaler, salbutamol inhaler, ibuprofen 400mg three times daily, and omeprazole. He reports good control of his conditions but mentions occasional indigestion despite the omeprazole. His recent blood results show HbA1c 52 mmol/mol, eGFR 58 ml/min/1.73m², and blood pressure 138/82 mmHg. Which single medication would be most appropriate to stop first?
Q84
A 75-year-old woman with heart failure (LVEF 38%), atrial fibrillation, hypertension, type 2 diabetes, and depression takes 12 regular medications. She attends with her daughter who manages her medications using a dosette box filled weekly by the pharmacy. The daughter reports her mother has been admitted to hospital three times in the past year with heart failure exacerbations, and they struggle to manage all the medications. Her current quality of life is poor. During a comprehensive medication review, which framework would be MOST appropriate to facilitate shared decision-making about treatment priorities?
Q85
You are developing a practice protocol for identifying patients who would benefit from structured medication review. According to NHS England guidance and the Network Contract DES requirements, which patient group should be prioritized for structured medication reviews in primary care?
Q86
A 73-year-old man with Parkinson's disease, type 2 diabetes, benign prostatic hyperplasia, and gastro-oesophageal reflux takes co-careldopa 25/100mg four times daily, pramipexole 0.88mg three times daily, metformin 1g twice daily, tamsulosin 400 micrograms daily, and lansoprazole 30mg daily. His wife reports he has been experiencing vivid dreams, visual hallucinations of people in the house, and increased confusion over the past 3 months. His Parkinson's symptoms are well controlled. What is the MOST appropriate medication management strategy?
Q87
During a practice audit of patients aged over 75 taking 10 or more regular medications, you identify that 22% are taking a proton pump inhibitor (PPI) long-term without documented indication. According to current evidence and guidance on deprescribing, which statement about long-term PPI use in older adults with polypharmacy is MOST accurate?
Q88
A 69-year-old woman with painful diabetic neuropathy, depression, hypertension, and osteoarthritis has been taking duloxetine 60mg twice daily for the past 2 years for neuropathic pain. She also takes metformin, amlodipine, ramipril, and paracetamol. She reports her pain is well controlled but has noticed increasing frequency of bruising and had two nosebleeds in the past month. She is not taking any antiplatelet or anticoagulant medication. Recent blood tests including full blood count, renal and liver function are normal. What is the MOST likely explanation for her bleeding symptoms?
Q89
You are reviewing the medication regimen of an 83-year-old man with heart failure (LVEF 32%), atrial fibrillation, type 2 diabetes, and stage 4 CKD (eGFR 24 ml/min/1.73m²). He takes bisoprolol 10mg daily, ramipril 2.5mg daily, furosemide 80mg twice daily, spironolactone 25mg daily, digoxin 125 micrograms daily, edoxaban 30mg daily, empagliflozin 10mg daily, and insulin glargine 28 units daily. Recent bloods show K⁺ 5.8 mmol/L, eGFR 24 ml/min/1.73m². He feels well with no symptoms. What is the MOST appropriate immediate management of his medication regimen?
Q90
A 71-year-old woman with rheumatoid arthritis, osteoporosis, type 2 diabetes, and ischaemic heart disease attends for medication review. She takes methotrexate 15mg weekly, folic acid 5mg weekly (taken day after methotrexate), prednisolone 5mg daily, alendronic acid 70mg weekly, metformin 1g twice daily, aspirin 75mg daily, atorvastatin 80mg daily, and ramipril 10mg daily. She reports good disease control but has developed mouth ulcers and feels increasingly tired. Recent blood tests show Hb 98 g/L (MCV 102 fL), WCC 3.2 × 10⁹/L, platelets 145 × 10⁹/L, eGFR 58 ml/min/1.73m². What is the MOST likely medication-related cause of her symptoms and blood results?
Chronic Disease Management UK Medical PG Practice Questions and MCQs
Question 81: During a structured medication review for a 69-year-old man taking 12 regular medications for multiple chronic conditions, you are applying the 7-Steps approach recommended by the General Medical Council. After identifying his current medications (Step 1) and determining which ones are essential, beneficial, or potentially harmful (Step 2), you identify that he is taking two proton pump inhibitors prescribed by different specialists. What is the next most appropriate step in the medication review process?
A. Calculate the patient's adherence rate using prescription collection data
B. Check for potential drug-drug interactions using the BNF (Correct Answer)
C. Contact both specialists to inform them of the duplication
D. Document the findings and arrange follow-up in 3 months
E. Stop one of the proton pump inhibitors immediately
Explanation: ***Check for potential drug-drug interactions using the BNF***- Step 3 of the **7-Steps approach** to medication review involves identifying **potential drug-drug interactions** and adverse drug reactions to ensure patient safety across the entire regimen.- Systematically checking for interactions, often using the **BNF**, must occur before tailoring or changing therapy, even if a clear duplication is found earlier.*Calculate the patient's adherence rate using prescription collection data*- Assessing **adherence** is a critical component of Step 4 (unnecessary medicines) or Step 5 (effectiveness), but is not the immediate priority after categorizing medications.- While collection data is useful, the **7-Steps framework** prioritizes safety and interaction screening (Step 3) before specific adherence audits.*Contact both specialists to inform them of the duplication*- Coordinating with specialists is part of **Step 7 (Communicate)**, which occurs at the end of the review process once all intended changes are finalized.- Communication is necessary for **integrated care**, but the clinical assessment must be completed before informing other clinicians of the proposed plan.*Document the findings and arrange follow-up in 3 months*- **Documentation** and monitoring represent the final stage (**Step 7**) of the structured review process and cannot replace the assessment steps.- Delaying the resolution of **polypharmacy** and duplication for three months would be inappropriate given the identified risk of dual PPI scripts.*Stop one of the proton pump inhibitors immediately*- Changes to therapy, such as **deprescribing**, should only occur in Step 5 (Optimisation) after discussing the clinical need and rationale with the patient in **Step 6**.- Stopping a medication immediately without completing the full **systematic safety assessment** or consulting the patient bypasses essential shared decision-making protocols.
Question 82: A 71-year-old woman with heart failure (NYHA class III), type 2 diabetes, and chronic kidney disease stage 3b attends for her six-monthly review. Her medications include bisoprolol 10mg once daily, ramipril 10mg once daily, spironolactone 25mg once daily, furosemide 80mg twice daily, metformin 500mg twice daily, empagliflozin 10mg once daily, and atorvastatin 40mg at night. Blood tests show: Na+ 136 mmol/L, K+ 5.8 mmol/L, urea 14.2 mmol/L, creatinine 168 µmol/L (eGFR 28 ml/min/1.73m²), HbA1c 58 mmol/mol. What is the single most appropriate immediate medication change?
A. Increase furosemide to 120mg twice daily
B. Reduce ramipril to 5mg once daily
C. Stop empagliflozin
D. Stop metformin
E. Stop spironolactone (Correct Answer)
Explanation: ***Stop spironolactone***- The patient has significant **hyperkalaemia** (K+ 5.8 mmol/L), which is a serious adverse effect exacerbated by spironolactone, a **potassium-sparing aldosterone antagonist**.- Given the patient's **reduced renal function** (eGFR 28 ml/min/1.73m²), spironolactone's potassium-sparing effect is amplified, necessitating immediate discontinuation to prevent life-threatening cardiac arrhythmias.*Increase furosemide to 120mg twice daily*- Increasing **furosemide**, a loop diuretic, would primarily address fluid overload, which is not highlighted as the most urgent issue, and would not directly correct **hyperkalaemia**.- A higher dose of furosemide could potentially lead to **volume depletion** and further worsen renal function, which is already compromised.*Reduce ramipril to 5mg once daily*- While **ACE inhibitors** like ramipril can contribute to hyperkalaemia, spironolactone is a more potent cause of potassium elevation, and discontinuing it should be the priority.- Ramipril is crucial for **cardioprotection** in heart failure and **renoprotection** in CKD; a dose reduction might be considered later if hyperkalaemia persists, but it is not the immediate, most appropriate change.*Stop empagliflozin*- **SGLT2 inhibitors** like empagliflozin have a low risk of causing hyperkalaemia and provide significant **cardio-renal protective benefits** in patients with heart failure and CKD, even at this eGFR.- Although its glucose-lowering efficacy reduces with lower eGFR, its benefits for **heart failure outcomes** typically warrant continuation until eGFR is much lower (e.g., <15 ml/min/1.73m²).*Stop metformin*- Metformin should be reviewed as the eGFR is below **30 ml/min/1.73m²** due to the risk of **lactic acidosis**, but it does not directly contribute to the patient's **hyperkalaemia**.- While metformin might need adjustment, addressing the immediate and potentially life-threatening hyperkalaemia caused by spironolactone takes precedence.
Question 83: A 74-year-old man with type 2 diabetes, hypertension, asthma, and osteoarthritis attends for a medication review. He takes 8 regular medications including metformin, gliclazide, ramipril, amlodipine, beclometasone/formoterol inhaler, salbutamol inhaler, ibuprofen 400mg three times daily, and omeprazole. He reports good control of his conditions but mentions occasional indigestion despite the omeprazole. His recent blood results show HbA1c 52 mmol/mol, eGFR 58 ml/min/1.73m², and blood pressure 138/82 mmHg. Which single medication would be most appropriate to stop first?
A. Ibuprofen (Correct Answer)
B. Metformin
C. Omeprazole
D. Amlodipine
E. Gliclazide
Explanation: ***Ibuprofen***- **Ibuprofen** should be stopped first because it is an **NSAID** which significantly increases the risk of **peptic ulceration** (suggested by persistent indigestion despite omeprazole) and **nephrotoxicity** in an elderly patient with an **eGFR of 58 ml/min/1.73m²**.- Chronic NSAID use can also exacerbate **asthma** and increase **cardiovascular risk**, making its discontinuation the most critical step in medication rationalization for this patient. *Metformin*- **Metformin** is a foundational medication for **Type 2 Diabetes**, and the patient's **HbA1c of 52 mmol/mol** indicates good glycemic control that should be maintained.- While **renal function** requires monitoring, metformin dose adjustment is typically considered when **eGFR falls below 45 ml/min/1.73m²**, which is not the case here. *Omeprazole*- **Omeprazole** is currently providing **gastroprotection** against the gastrointestinal side effects of **ibuprofen**.- Stopping omeprazole while the patient is still on a high-dose NSAID would significantly increase the risk of a **gastrointestinal bleed** or ulcer, making it an inappropriate first medication to discontinue. *Amlodipine*- **Amlodipine** is an effective **antihypertensive** medication, and the patient's blood pressure is currently well-controlled at **138/82 mmHg**.- There is no clinical indication that amlodipine is causing the patient's indigestion or contributing to renal decline, thus stopping it is not warranted. *Gliclazide*- **Gliclazide**, a sulfonylurea, is essential for maintaining the patient's **glycemic control** as indicated by his target **HbA1c of 52 mmol/mol**.- Discontinuing gliclazide without a clinical need could lead to a **loss of metabolic control** and **hyperglycemia**, which is detrimental for a diabetic patient.
Question 84: A 75-year-old woman with heart failure (LVEF 38%), atrial fibrillation, hypertension, type 2 diabetes, and depression takes 12 regular medications. She attends with her daughter who manages her medications using a dosette box filled weekly by the pharmacy. The daughter reports her mother has been admitted to hospital three times in the past year with heart failure exacerbations, and they struggle to manage all the medications. Her current quality of life is poor. During a comprehensive medication review, which framework would be MOST appropriate to facilitate shared decision-making about treatment priorities?
A. The QRISK3 cardiovascular risk calculator to quantify benefits of each medication
B. The Edmonton Frail Scale to assess frailty and determine which medications to stop
C. A patient-centred approach exploring the patient's goals, priorities, and what matters most to them (Correct Answer)
D. The Charlson Comorbidity Index to calculate life expectancy and stop preventative medications
E. The Rockwood Clinical Frailty Scale to categorize frailty level and adjust all medications accordingly
Explanation: ***A patient-centred approach exploring the patient's goals, priorities, and what matters most to them***
- This approach is crucial in **complex multimorbidity** and **polypharmacy**, especially when a patient's **quality of life** is poor and **treatment burden** is high, as it directly addresses their values and preferences.
- It facilitates **shared decision-making** by focusing on what the patient and their family prioritize, whether it's symptom management, functional independence, or reducing medication load, rather than solely disease-specific guidelines.
*The QRISK3 cardiovascular risk calculator to quantify benefits of each medication*
- **QRISK3** is designed for **primary prevention** in a general population and has limited utility for a 75-year-old with established **heart failure** and multiple comorbidities.
- It quantifies future risk but doesn't provide a framework for discussing current **treatment burden**, patient values, or making decisions about **deprescribing** in complex cases.
*The Edmonton Frail Scale to assess frailty and determine which medications to stop*
- While the **Edmonton Frail Scale** helps identify **frailty**, it is an assessment tool, not a framework for **shared decision-making** about treatment priorities.
- Determining medication changes solely based on a frailty score overlooks the patient's personal **goals**, potential benefits of some medications, and the importance of a holistic discussion.
*The Charlson Comorbidity Index to calculate life expectancy and stop preventative medications*
- The **Charlson Comorbidity Index** predicts **mortality risk** based on comorbidities but does not provide a comprehensive framework for patient-centered **shared decision-making** regarding their current **quality of life** or treatment priorities.
- Stopping preventative medications solely based on a predicted life expectancy without considering patient preferences can be inappropriate and misses the opportunity for a broader discussion about care goals.
*The Rockwood Clinical Frailty Scale to categorize frailty level and adjust all medications accordingly*
- The **Rockwood Clinical Frailty Scale** is an excellent tool for **categorizing frailty** and informing clinical judgment, but it's primarily an assessment tool.
- It does not, on its own, provide a structured framework for a **shared decision-making conversation** about a patient's individual **goals** and priorities in the context of polypharmacy and multimorbidity.
Question 85: You are developing a practice protocol for identifying patients who would benefit from structured medication review. According to NHS England guidance and the Network Contract DES requirements, which patient group should be prioritized for structured medication reviews in primary care?
A. All patients taking any regular medication regardless of age or number of conditions
B. Patients aged 75 years and over taking 5 or more medications, or patients with problematic polypharmacy (Correct Answer)
C. Only patients with dementia taking any regular medications
D. Patients aged 65 years and over taking 3 or more medications
E. Only patients who request a medication review themselves
Explanation: ***Patients aged 75 years and over taking 5 or more medications, or patients with problematic polypharmacy***
- According to **NHS England guidance** and the **Network Contract DES**, patients aged **75 years and over** taking **5 or more medications** are a top priority for **Structured Medication Reviews (SMR)** to reduce medication-related harm.
- This cohort is specifically targeted to address **problematic polypharmacy**, where the risks of multiple medications may outweigh clinical benefits, necessitating a shared decision-making approach.
*All patients taking any regular medication regardless of age or number of conditions*
- This approach is not feasible or recommended as it does not **prioritize resources** towards those at the highest risk of **adverse drug reactions** or **suboptimal medication use**.
- **Structured Medication Reviews (SMRs)** are comprehensive clinical assessments meant for specific **high-risk groups**, not a universal screening tool for all prescribing.
*Only patients with dementia taking any regular medications*
- While patients with **dementia** or those in **care homes** are indeed a priority group within the broader SMR guidance, prioritizing them *exclusively* incorrectly omits other significant high-risk elderly populations.
- The guidance encompasses a broader range of clinical vulnerabilities, including those with **frailty**, **complex multi-morbidity**, or recent hospital discharge, beyond just dementia.
*Patients aged 65 years and over taking 3 or more medications*
- This threshold is lower than the specific **NHS England criteria** for the primary SMR priority group, which defines it as those aged **75 and over** on **5 or more medications**.
- Using a lower age or medication count would capture a much larger population than the **Network Contract DES requirements** currently mandate for structured clinical prioritization, potentially overstretching resources.
*Only patients who request a medication review themselves*
- **Structured Medication Reviews (SMRs)** must be **proactive and systematic**, identifying high-risk patients based on clinical data and agreed criteria rather than being purely **reactive** to patient requests.
- Relying solely on patient requests would fail to identify many **vulnerable or frail** individuals who may not recognize or be able to articulate their need for a medication review.
Question 86: A 73-year-old man with Parkinson's disease, type 2 diabetes, benign prostatic hyperplasia, and gastro-oesophageal reflux takes co-careldopa 25/100mg four times daily, pramipexole 0.88mg three times daily, metformin 1g twice daily, tamsulosin 400 micrograms daily, and lansoprazole 30mg daily. His wife reports he has been experiencing vivid dreams, visual hallucinations of people in the house, and increased confusion over the past 3 months. His Parkinson's symptoms are well controlled. What is the MOST appropriate medication management strategy?
A. Stop co-careldopa immediately as it is the most common cause of psychosis in Parkinson's disease
B. Add quetiapine to manage the psychotic symptoms while continuing all Parkinson's medications
C. Gradually reduce and stop pramipexole as dopamine agonists commonly cause neuropsychiatric side effects (Correct Answer)
D. Increase co-careldopa dose to improve dopaminergic control and reduce psychotic symptoms
E. Stop tamsulosin as alpha-blockers can cause hallucinations in older adults
Explanation: ***Gradually reduce and stop pramipexole as dopamine agonists commonly cause neuropsychiatric side effects***- **Dopamine agonists** like **pramipexole** are more likely than levodopa to cause **neuropsychiatric adverse effects**, including **visual hallucinations**, confusion, and vivid dreams.- The management hierarchy for Parkinson's psychosis dictates withdrawing non-essential medications first; dopamine agonists should be **tapered gradually** to avoid **Dopamine Agonist Withdrawal Syndrome (DAWS)**.*Stop co-careldopa immediately as it is the most common cause of psychosis in Parkinson's disease*- **Levodopa (co-careldopa)** is actually the last medication to be reduced because it provides the best **motor symptom** control and is less frequently associated with psychosis than agonists.- Abrupt cessation of dopaminergic therapy can trigger **neuroleptic malignant-like syndrome**, a life-threatening complication.*Add quetiapine to manage the psychotic symptoms while continuing all Parkinson's medications*- While **quetiapine** or **clozapine** are used for Parkinson's psychosis, the first-line intervention must be the **reduction or withdrawal** of precipitating dopaminergic medications.- Adding more drugs increases the risk of **polypharmacy** and side effects before addressing the underlying pharmacological cause.*Increase co-careldopa dose to improve dopaminergic control and reduce psychotic symptoms*- Increasing the dopaminergic load will **exacerbate hallucinations** and confusion rather than treating them.- **Psychosis** in Parkinson's is typically a result of overstimulation of the **mesolimbic dopaminergic pathways**.*Stop tamsulosin as alpha-blockers can cause hallucinations in older adults*- **Tamsulosin** primarily acts on **alpha-1 receptors** in the bladder neck and is not a recognized cause of visual hallucinations.- The patient's symptoms are classic markers of **dopaminergic toxicity** rather than an adverse reaction to BPH treatment.
Question 87: During a practice audit of patients aged over 75 taking 10 or more regular medications, you identify that 22% are taking a proton pump inhibitor (PPI) long-term without documented indication. According to current evidence and guidance on deprescribing, which statement about long-term PPI use in older adults with polypharmacy is MOST accurate?
A. PPIs should never be stopped once started due to severe rebound acid hypersecretion causing gastric ulceration
B. Long-term PPI use is associated with increased risks of Clostridium difficile infection, osteoporotic fractures, and possible hypomagnesaemia (Correct Answer)
C. PPIs provide cardiovascular protection in patients taking aspirin and should be continued indefinitely in all patients over 75
D. Stopping PPIs requires hospital admission for gastroprotection monitoring
E. PPIs have no significant drug interactions and are safe indefinitely in all patients with polypharmacy
Explanation: ***Long-term PPI use is associated with increased risks of Clostridium difficile infection, osteoporotic fractures, and possible hypomagnesaemia***
- Prolonged use of **proton pump inhibitors (PPIs)** reduces gastric acidity, diminishing a key defense against pathogens, thus increasing the risk of **Clostridium difficile infection** and other enteric infections.
- Chronic PPI use can impair the absorption of essential nutrients like **calcium** and **magnesium**, leading to an increased risk of **osteoporotic fractures** and **hypomagnesaemia**, especially in older adults.
*PPIs should never be stopped once started due to severe rebound acid hypersecretion causing gastric ulceration*
- While **rebound acid hypersecretion** can occur upon stopping PPIs, it is usually managed by a **gradual dose taper** or short-term symptomatic treatment, not typically resulting in severe gastric ulceration.
- The principle of **deprescribing** inappropriate or unnecessary medications in older adults outweighs the temporary discomfort of rebound acidity, which can be mitigated.
*PPIs provide cardiovascular protection in patients taking aspirin and should be continued indefinitely in all patients over 75*
- PPIs primarily provide **gastroprotection** against upper gastrointestinal bleeding in patients taking aspirin or NSAIDs, but they do not offer independent **cardiovascular protection**.
- Decisions for long-term PPI use with aspirin should be individualized based on **gastrointestinal bleeding risk factors**, rather than continued indefinitely in all older patients.
*Stopping PPIs requires hospital admission for gastroprotection monitoring*
- **Deprescribing PPIs** is a common practice that can typically be managed safely in an **outpatient primary care setting**, with careful patient education and monitoring for symptom recurrence.
- Hospital admission is generally not required for PPI cessation unless there are severe underlying conditions or acute complications demanding inpatient care.
*PPIs have no significant drug interactions and are safe indefinitely in all patients with polypharmacy*
- PPIs have several **significant drug interactions**, including with **clopidogrel** (reducing its efficacy) and certain antiretrovirals, antifungals, and iron salts due to altered gastric pH.
- Long-term safety in patients with **polypharmacy** is a concern, as PPIs can contribute to adverse effects like **Vitamin B12 deficiency**, **acute interstitial nephritis**, and potential **chronic kidney disease**, adding to the overall medication burden.
Question 88: A 69-year-old woman with painful diabetic neuropathy, depression, hypertension, and osteoarthritis has been taking duloxetine 60mg twice daily for the past 2 years for neuropathic pain. She also takes metformin, amlodipine, ramipril, and paracetamol. She reports her pain is well controlled but has noticed increasing frequency of bruising and had two nosebleeds in the past month. She is not taking any antiplatelet or anticoagulant medication. Recent blood tests including full blood count, renal and liver function are normal. What is the MOST likely explanation for her bleeding symptoms?
A. Undiagnosed platelet function disorder revealed by detailed haematological testing
B. Drug interaction between duloxetine and ramipril causing vasculitis
C. Duloxetine affecting serotonin reuptake in platelets leading to platelet dysfunction (Correct Answer)
D. Occult metformin-induced thrombocytopenia despite normal platelet count
E. Amlodipine causing capillary fragility and increased bleeding tendency
Explanation: ***Duloxetine affecting serotonin reuptake in platelets leading to platelet dysfunction***
- **Duloxetine**, an SNRI, inhibits the **serotonin transporter (SERT)** on platelets, preventing them from taking up serotonin which is essential for **platelet aggregation**.
- This leads to a functional **platelet defect** rather than a quantitative one, resulting in symptoms like **bruising** and **epistaxis** even when the **full blood count** is normal.
*Undiagnosed platelet function disorder revealed by detailed haematological testing*
- While it presents similarly to drug-induced dysfunction, the **new onset** of symptoms synchronized with chronic high-dose medication makes a late-presentation genetic disorder highly unlikely.
- The patient has no prior history of abnormal bleeding during **surgery** or **trauma**, which would typically be present in a primary disorder.
*Drug interaction between duloxetine and ramipril causing vasculitis*
- There is no clinical or pharmacological evidence to support a **drug interaction** between SNRIs and ACE inhibitors that manifests as **vasculitis**.
- Vasculitis usually presents with **palpable purpura**, systemic malaise, or organ involvement, rather than isolated **bruising and nosebleeds**.
*Occult metformin-induced thrombocytopenia despite normal platelet count*
- **Thrombocytopenia** is defined by a low platelet count; the term "occult" is not applicable when a **normal full blood count** has been confirmed.
- **Metformin** is not typically associated with bone marrow suppression or drug-induced immune destruction of platelets.
*Amlodipine causing capillary fragility and increased bleeding tendency*
- **Amlodipine** is a calcium channel blocker commonly associated with **peripheral oedema**, but it does not cause **capillary fragility** or affect the coagulation cascade.
- Bleeding tendencies in elderly patients on amlodipine are usually due to **comorbidities** or concurrent use of antiplatelets, not the drug itself.
Question 89: You are reviewing the medication regimen of an 83-year-old man with heart failure (LVEF 32%), atrial fibrillation, type 2 diabetes, and stage 4 CKD (eGFR 24 ml/min/1.73m²). He takes bisoprolol 10mg daily, ramipril 2.5mg daily, furosemide 80mg twice daily, spironolactone 25mg daily, digoxin 125 micrograms daily, edoxaban 30mg daily, empagliflozin 10mg daily, and insulin glargine 28 units daily. Recent bloods show K⁺ 5.8 mmol/L, eGFR 24 ml/min/1.73m². He feels well with no symptoms. What is the MOST appropriate immediate management of his medication regimen?
A. Stop empagliflozin as it is contraindicated with eGFR <30 ml/min/1.73m² and may be contributing to hyperkalaemia
B. Stop spironolactone immediately due to hyperkalaemia and severe CKD (Correct Answer)
C. Reduce ramipril dose to 1.25mg daily to lower potassium levels while maintaining cardiovascular protection
D. Stop digoxin as it accumulates in renal impairment and check digoxin level urgently
E. Admit to hospital immediately for management of life-threatening hyperkalaemia
Explanation: ***Stop spironolactone immediately due to hyperkalaemia and severe CKD***
- Spironolactone is a **mineralocorticoid receptor antagonist (MRA)** that significantly increases the risk of **hyperkalaemia**, especially in patients with **severe renal impairment** (eGFR <30 mL/min/1.73m²).
- With the patient's **eGFR of 24 ml/min/1.73m²** and a potassium level of **5.8 mmol/L**, discontinuing spironolactone is the most appropriate and immediate action to prevent worsening hyperkalaemia.
*Stop empagliflozin as it is contraindicated with eGFR <30 ml/min/1.73m² and may be contributing to hyperkalaemia*
- While **SGLT2 inhibitors** like empagliflozin have historical eGFR cutoffs for initiation, current guidelines recommend continuing them for **cardiorenal protection** in heart failure and CKD even at lower eGFRs if already established.
- SGLT2 inhibitors typically have a **potassium-lowering** or neutral effect and are therefore unlikely to be the primary cause of this patient's hyperkalaemia.
*Reduce ramipril dose to 1.25mg daily to lower potassium levels while maintaining cardiovascular protection*
- While **ACE inhibitors** like ramipril can contribute to **hyperkalaemia**, their effect is generally less pronounced than that of MRAs, and they provide significant **cardiovascular benefits** in heart failure.
- Prioritizing the cessation of the more potent hyperkalaemic agent (spironolactone) while preserving the beneficial effects of **RAAS inhibition** is crucial in this scenario.
*Stop digoxin as it accumulates in renal impairment and check digoxin level urgently*
- **Digoxin** is primarily cleared renally, and a dose adjustment or monitoring of levels is necessary in **CKD** to prevent toxicity; however, digoxin does not directly cause **hyperkalaemia**.
- Although a dose of 125 micrograms daily might be high for an eGFR of 24, managing potential digoxin toxicity is not the immediate priority for an asymptomatic patient with elevated potassium.
*Admit to hospital immediately for management of life-threatening hyperkalaemia*
- A potassium level of **5.8 mmol/L** is considered **moderate hyperkalaemia**. Since the patient is **asymptomatic** and no ECG changes are mentioned, it can often be managed in the outpatient setting by medication adjustment.
- **Life-threatening hyperkalaemia**, typically defined as potassium **≥6.5 mmol/L** or any level with **ECG changes** (e.g., peaked T waves, QRS widening), would warrant immediate hospital admission for urgent intervention.
Question 90: A 71-year-old woman with rheumatoid arthritis, osteoporosis, type 2 diabetes, and ischaemic heart disease attends for medication review. She takes methotrexate 15mg weekly, folic acid 5mg weekly (taken day after methotrexate), prednisolone 5mg daily, alendronic acid 70mg weekly, metformin 1g twice daily, aspirin 75mg daily, atorvastatin 80mg daily, and ramipril 10mg daily. She reports good disease control but has developed mouth ulcers and feels increasingly tired. Recent blood tests show Hb 98 g/L (MCV 102 fL), WCC 3.2 × 10⁹/L, platelets 145 × 10⁹/L, eGFR 58 ml/min/1.73m². What is the MOST likely medication-related cause of her symptoms and blood results?
A. Ramipril is causing bone marrow suppression and should be switched to an alternative antihypertensive
B. Metformin is causing vitamin B12 deficiency leading to macrocytic anaemia
C. Alendronic acid is causing gastrointestinal blood loss leading to anaemia
D. Inadequate folic acid supplementation with methotrexate is causing folate deficiency (Correct Answer)
E. Atorvastatin is interacting with methotrexate causing increased toxicity
Explanation: ***Inadequate folic acid supplementation with methotrexate is causing folate deficiency***
- **Methotrexate** is a **folate antagonist** that inhibits **dihydrofolate reductase**; inadequate supplementation leads to **macrocytic anaemia**, **leukopenia**, and painful **mucosal ulcers**.
- While the patient takes a weekly dose, the presence of **pancytopenia** (low Hb, WCC, and borderline platelets) and symptoms suggests she requires a higher frequency of **folic acid** (e.g., 5mg daily except on methotrexate day) to counteract toxicity.
*Ramipril is causing bone marrow suppression and should be switched to an alternative antihypertensive*
- **ACE inhibitors** like ramipril are not typically associated with **bone marrow suppression** or macrocytic changes.
- Their most common serious side effects relate to **renal function impairment**, hyperkalaemia, or chronic dry cough, rather than cytopenias.
*Metformin is causing vitamin B12 deficiency leading to macrocytic anaemia*
- **Metformin** can indeed cause **Vitamin B12 deficiency** and macrocytosis, but it does not explain the acute development of **mouth ulcers**.
- B12 deficiency usually presents over a much longer period and would not typically cause the **leukopenia** seen in this acute clinical picture as prominently as folate depletion.
*Alendronic acid is causing gastrointestinal blood loss leading to anaemia*
- GI blood loss from bisphosphonate-induced **esophagitis** or ulceration would result in an **iron-deficiency anaemia**, which is characteristically **microcytic** (low MCV).
- This patient has a **macrocytic** (high MCV) picture, which is inconsistent with simple chronic blood loss.
*Atorvastatin is interacting with methotrexate causing increased toxicity*
- There is no clinically significant pharmacological interaction between **atorvastatin** and methotrexate that leads to **hematologic toxicity**.
- Methotrexate toxicity is more commonly precipitated by drugs that compete for renal excretion, such as **NSAIDs** or **Penicillins**, or conditions like worsening **renal impairment** (eGFR 58).
